Analysts at Barclays PLC assumed coverage on shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in a report issued on Monday. The firm set an “equal weight” rating on the stock.

Several other research firms also recently weighed in on TEVA. Mizuho reissued a “buy” rating and issued a $70.00 price target (down from $75.00) on shares of Teva Pharmaceutical Industries in a research note on Friday, August 5th. Guggenheim reissued a “buy” rating and issued a $80.00 price target on shares of Teva Pharmaceutical Industries in a research note on Monday, August 15th. Leerink Swann reaffirmed an “outperform” rating and set a $66.00 price objective on shares of Teva Pharmaceutical Industries in a research note on Tuesday, August 16th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $75.00 price objective on shares of Teva Pharmaceutical Industries in a research note on Tuesday, July 26th. Finally, Zacks Investment Research raised shares of Teva Pharmaceutical Industries from a “sell” rating to a “hold” rating in a research note on Monday, July 18th. Ten research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Teva Pharmaceutical Industries has a consensus rating of “Buy” and a consensus price target of $65.44.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) opened at 40.65 on Monday. The company has a 50-day moving average of $43.93 and a 200 day moving average of $50.26. The company has a market cap of $37.15 billion, a PE ratio of 27.15 and a beta of 0.73. Teva Pharmaceutical Industries has a 12 month low of $37.82 and a 12 month high of $66.55.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. PGGM Investments increased its position in Teva Pharmaceutical Industries by 64.7% in the second quarter. PGGM Investments now owns 1,344,928 shares of the company’s stock valued at $67,556,000 after buying an additional 528,470 shares during the last quarter. CNA Financial Corp acquired a new position in Teva Pharmaceutical Industries during the second quarter valued at $2,662,000. Psagot Investment House Ltd. increased its position in Teva Pharmaceutical Industries by 81.9% in the second quarter. Psagot Investment House Ltd. now owns 1,070,005 shares of the company’s stock valued at $53,746,000 after buying an additional 481,820 shares during the last quarter. Deprince Race & Zollo Inc. increased its position in Teva Pharmaceutical Industries by 614.8% in the second quarter. Deprince Race & Zollo Inc. now owns 566,084 shares of the company’s stock valued at $28,434,000 after buying an additional 486,894 shares during the last quarter. Finally, RNC Capital Management LLC increased its position in Teva Pharmaceutical Industries by 384.5% in the second quarter. RNC Capital Management LLC now owns 392,970 shares of the company’s stock valued at $19,739,000 after buying an additional 311,856 shares during the last quarter. Institutional investors and hedge funds own 63.00% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.